Sparsentan
Focal Segmental Glomerulosclerosis (FSGS)
Phase 3Active (DUPLEX Study)
Key Facts
Indication
Focal Segmental Glomerulosclerosis (FSGS)
Phase
Phase 3
Status
Active (DUPLEX Study)
Company
About Travere Therapeutics
Travere Therapeutics is a San Diego-based biopharma leader dedicated to rare diseases, particularly in nephrology and metabolism. The company has successfully transitioned to commercial operations with a fully approved therapy for IgA nephropathy (IgAN) and a late-stage pipeline targeting conditions like focal segmental glomerulosclerosis (FSGS) and classical homocystinuria (HCU). Its strategy leverages deep community engagement and scientific expertise to navigate complex development pathways and establish new standards of care in niche markets.
View full company profileTherapeutic Areas
Other Focal Segmental Glomerulosclerosis (FSGS) Drugs
| Drug | Company | Phase |
|---|---|---|
| KRP-205 | Kissei Pharmaceutical | Phase II |
| DMX-200 | Amicus Therapeutics | Phase 3 |
| Voclosporin | Aurinia Pharmaceuticals | Phase 2 |